Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort

Ladep, Nimzing G.; Agaba, Patricia A; Agbaji, Oche; Muazu, Auwal; Ugoagwu, Placid; Imade, Godwin; Cooke, Graham; McCormack, Sheena; Taylor‐Robinson, Simon D.; Idoko, John; Kanki, Phyllis J.

doi:10.3748/wjg.v19.i10.1602

Cited by 45 publications

(39 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, higher baseline HIV RNA in HIV/HBV-coinfected participants has been documented [13]. In this study, similar to studies conducted in South Africa and Kenya, there was no difference in HIV viral load suppression between the 2 groups [1, 15, 22].…”

Section: Discussionsupporting

confidence: 80%

Slow CD4+ T-Cell Recovery in Human Immunodeficiency Virus/Hepatitis B Virus-Coinfected Patients Initiating Truvada-Based Combination Antiretroviral Therapy in Botswana

Anderson

Gaseitsiwe

Moyo

et al. 2016

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Background. Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) coinfection has emerged as an important cause of morbidity and mortality. We determined the response to Truvada-based first-line combination antiretroviral therapy (cART) in HIV/HBV-coinfected verus HIV-monoinfected patients in Botswana.Methods. Hepatitis B virus surface antigen (HBsAg), HBV e antigen (HBeAg), and HBV deoxyribonucleic acid (DNA) load were determined from baseline and follow-up visits in a longitudinal cART cohort of Truvada-based regimen. We assessed predictors of HBV serostatus and viral suppression (undetectable HBV DNA) using logistic regression techniques.Results. Of 300 participants, 28 were HBsAg positive, giving an HIV/HBV prevalence of 9.3% (95% confidence interval [CI], 6.3–13.2), and 5 of these, 17.9% (95% CI, 6.1–36.9), were HBeAg positive. There was a reduced CD4+ T-cell gain in HIV/HBV-coinfected compared with HIV-monoinfected patients. Hepatitis B virus surface antigen and HBeAg loss was 38% and 60%, respectively, at 24 months post-cART initiation. The HBV DNA suppression rates increased with time on cART from 54% to 75% in 6 and 24 months, respectively.Conclusions. Human immunodeficiency virus/HBV coinfection negatively affected immunologic recovery compared with HIV-1C monoinfection. Hepatitis B virus screening before cART initiation could help improve HBV/HIV treatment outcomes and help determine treatment options when there is a need to switch regimens.

show abstract

Section: Discussionsupporting

confidence: 80%

Slow CD4+ T-Cell Recovery in Human Immunodeficiency Virus/Hepatitis B Virus-Coinfected Patients Initiating Truvada-Based Combination Antiretroviral Therapy in Botswana

Anderson

Gaseitsiwe

Moyo

et al. 2016

Open Forum Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…The results obtained in the study were similar to those obtained by Ladep et al in Nigeria, where the rate of HBV/HIV coinfection was 17.8% using HBsAg as a marker [10]. Also, Utsumi et al [11] in Indonesia and Geretti et al [12] in China reported results consistent with our findings (15.3%, and 16.7%, respectively), using ELISA to detect HBsAg.…”

Section: Discussionsupporting

confidence: 82%

Molecular Detection of Hepatitis B Virus DNA in Human Immunodeficiency Virus Infected Patients in Khartoum, Sudan

Elfaki¹,

Enan²,

Elkhidir³

et al. 2016

Mol Biol

View full text Add to dashboard Cite

show abstract

“…HCV infection is relatively common in HIV-infected people, and its management is especially difficult in resource-limited areas such as sub-Saharan African countries [9]. The reported prevalence of HCV-HIV co-infection in this part of the continent is highly variable [10][11][12][13][14] and is probably underestimated because it is often based on serology. Indeed, HCV RNA was detected in six HIV-infected donors who were HCV seronegative at screening.…”

Section: Discussionmentioning

confidence: 99%

Higher levels of hepatitis C virus RNA found in blood donors co-infected with HIV as compared to HCV mono-infected donors

Alidjinou

Moukassa

Ataboho

et al. 2014

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Hepatitis C virus (HCV) infection and human immunodeficiency virus (HIV) infections are public health problems in subSaharan countries such as the Republic of Congo. HIV infection could impact the characteristics of HCV infection in co-infected people. We investigated HCV-HIV co-infection among blood donors in Congo. Methodology: Ninety-nine HIV-positive and/or HCV-seropositive blood donors were selected during screening and subsequently tested for aminotransferases and HCV RNA. Results: A total of 29 donors were found positive for HCV RNA (HCV-infected individuals), including 19/60 (31.66%) HIV donors (coinfected) and 10/39 (25.64%) non-HIV donors (mono-infected). Most of the co-infected donors (17/19) displayed a high viral load (> 5 log). The median HCV RNA level was at least 2 logs higher in co-infected people. The levels of alanine aminotransferase (ALT) were also slightly higher in co-infected donors than in HCV mono-infected donors. Conclusion: This study reports HCV-HIV co-infection among blood donors in Congo and shows that HCV viral load is higher in HIV donors.

show abstract

Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort

Abstract: High rates of HBV and HCV infections were found in this HIV cohort. CD4 recovery was significantly diminished in patients with HBV co-infection.

Cited by 45 publications

References 27 publications

Slow CD4+ T-Cell Recovery in Human Immunodeficiency Virus/Hepatitis B Virus-Coinfected Patients Initiating Truvada-Based Combination Antiretroviral Therapy in Botswana

Slow CD4+ T-Cell Recovery in Human Immunodeficiency Virus/Hepatitis B Virus-Coinfected Patients Initiating Truvada-Based Combination Antiretroviral Therapy in Botswana

Molecular Detection of Hepatitis B Virus DNA in Human Immunodeficiency Virus Infected Patients in Khartoum, Sudan

Higher levels of hepatitis C virus RNA found in blood donors co-infected with HIV as compared to HCV mono-infected donors

Contact Info

Product

Resources

About